ClinicalTrials.gg

Program

barzolvolimab

Also written as “CDX-0159” and “Barzolvolimab”.

Its studies are mostly in Chronic Urticaria · Prurigo · Dermatitis, Atopic · Eosinophilic Esophagitis, led by Celldex Therapeutics.

Furthest: phase 3, since May 31, 202414 company-led studies, 6 open or runningNext primary completion: Jun 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Celldex Therapeutics146 open or runningphase 3since May 31, 2024Oct 29, 2019Jun 2028phase 3 · NCT07266402

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2019First study: phase 1 study in Healthy SubjectsFirst studyNCT04146129 · 32 enrolled · United States
  2. Aug 31, 2020Phase 1 study in Chronic UrticariaNCT04538794 · 45 enrolled · United States, Germany
  3. Sep 8, 2020Phase 1 study in Cold UrticariaNCT04548869 · 41 enrolled · Germany
  4. Jun 22, 2021Phase 1 study in Prurigo NodularisNCT04944862 · 24 enrolled · United States, Germany, Poland
  5. Jul 29, 2021Phase 1 study in Healthy SubjectsNCT05031624 · 32 enrolled · United States
  6. May 5, 2022Phase 2 study in Chronic UrticariaNCT05368285 · 208 enrolled · United States, Bulgaria, Estonia and more
  7. Jun 1, 2022Phase 2 study in Chronic Inducible UrticariaNCT05405660 · 196 enrolled · United States, Bulgaria, Estonia and more
  8. Mar 7, 2023Phase 2 study in Eosinophilic EsophagitisNCT05774184 · 86 enrolled · United States, Australia, Canada and more
  9. Mar 27, 2024Phase 2 study in Prurigo NodularisNCT06366750 · 140 enrolled · United States, Canada, Croatia and more
  10. May 31, 2024Phase 3 study in Chronic UrticariaNCT06445023 · 963 enrolled · United States, Argentina, Belgium and more
  11. Jun 7, 2024Phase 3 study in Chronic UrticariaNCT06455202 · 976 enrolled · United States, Australia, Bulgaria and more
  12. Dec 9, 2024Phase 2 study in Dermatitis, AtopicNCT06727552 · 131 enrolled · United States
  13. Nov 19, 20252 phase 3 studiesNCT07266402, NCT07256392

Ahead

  1. Jun 2028Primary completion: phase 3 study in Chronic Inducible UrticariaNCT07266402
  2. Sep 2028Primary completion: phase 3 study in Chronic UrticariaNCT07256392

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07256392Chronic Urticaria · United States, Argentina, Australia and more3By invitationSep 20281,370
NCT07266402Chronic Inducible Urticaria · United States, Germany, Lithuania and more3RecruitingJun 2028240
NCT06727552Dermatitis, Atopic · United States2Active, not recruitingMay 6, 2026131
NCT06455202Chronic Urticaria · United States, Australia, Bulgaria and more3Active, not recruitingAug 4, 2026976
NCT06445023Chronic Urticaria · United States, Argentina, Belgium and more3Active, not recruitingAug 12, 2026963
NCT06366750Prurigo Nodularis · United States, Canada, Croatia and more2Active, not recruitingMar 17, 2026140
NCT05774184Eosinophilic Esophagitis · United States, Australia, Canada and more2CompletedJun 4, 202586
NCT05405660Chronic Inducible Urticaria · United States, Bulgaria, Estonia and more2CompletedJun 12, 2024196
NCT05368285Chronic Urticaria · United States, Bulgaria, Estonia and more2CompletedSep 28, 2023208
NCT05031624Healthy Subjects · United States1CompletedJan 14, 202232
NCT04944862Prurigo Nodularis · United States, Germany, Poland1CompletedJul 31, 202324
NCT04548869Cold Urticaria · Germany1CompletedDec 16, 202241
NCT04538794Chronic Urticaria · United States, Germany1CompletedJan 17, 202345
NCT04146129Healthy Subjects · United States1CompletedApr 6, 202032

How it is read

Names in the registry

  • “barzolvolimab”, 7 entries
  • “CDX-0159”, 5 entries
  • “Barzolvolimab”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.